Welcome to the Ring: Bipolar Depression Faculty Debate
neuroscienceCME Webcast
Premiere Date: Friday, May 1, 2015This activity offers CE credit for:
- Physicians (CME)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, May 1, 2016
Note: Credit Is No Longer Available
 | Joseph R. Calabrese, MD Bipolar Disorders Research Chair and Professor of Psychiatry Case Western Reserve University School of Medicine Director, Mood Disorders Program University Hospitals Case Medical Center Cleveland, OH |
 | Robert M.A. Hirschfeld, MD Titus H. Harris Chair Harry K. Davis Professor Professor and Chairperson Department of Psychiatry University of Texas Medical Branch Galveston, TX |
 | Charles B. Nemeroff, MD, PhD Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX |
Let’s get ready to rumble!
This video is a replay of one of the most entertaining and clinically impactful plenary sessions from the 7th Annual Chair Summit: Master Class for Neuroscience Professional Development held in Tampa Florida on September 11-13, 2014. Focusing on the many complexities of bipolar depression and how that impacts treatment decisions, Dr. Calabrese and Dr. Hirschfeld “battle it out”, with Dr. Nemeroff as the referee. To kick it off in round one, faculty talk about diagnosis, then things heat up in round two with discussion about short-term treatment, and the battle ends with round three honing in on maintenance treatment.
There is a nominal fee to view the Chair Summit videos. Please click on the "Begin Activity" link for more information.
At the end of this CE activity, participants should be able to:
- Recognize the complexities of bipolar depression that impact treatment decisions
This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.
Physicians, physician assistants, nurse practitioners, and other nonphysician health care professionals with an interest in psychiatry, neurology, and the neurosciences.
CME Credit (Physicians):
CME Credit (Physicians): CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST7012 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Calabrese has disclosed that he receives research support from Abbott Laboratories; AstraZeneca; Cephalon, Inc.; Cleveland Foundation; Eli Lilly and Company; GlaxoSmithKline; Lundbeck; NARSAD; Stanley Medical Research Institute. He serves as a consultant to Biomedical Development Corporation; Convergent Health Solutions, LLC; Dainippon Sumitomo Pharma Co., Ltd.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Health & Wellness Partners; Hoffmann-La Roche, Inc.; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals USA, Inc.; Web ID. He receives federal funding from the Department of Defense; Health Resources and Services Administration; National Institute of Mental Health. He has also had CME lectures supported by AstraZeneca; Benecke; Dainippon Sumitomo Pharma Co., Ltd.; Elan Pharmaceuticals, Inc.; Forest Laboratories, Inc.; GlasxoSmithKline; Health & Wellness Partners: Lundbeck;
Medwiz Healthcare; Otsuka America Pharmaceutical, Inc.; ProMedica; Spirant Communication Pvt. Ltd.; Scientia Ltd; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals USA, Inc.; Teva Pharmaceuticals.
Dr. Hirschfeld has disclosed that he receives royalties from Jones and Bartlett Publisher. He serves as a consultant to Equinox; GlaxoSmithKline; GME Global Medical; Merck Manual Editorial Board.
Dr. Nemeroff has disclosed that he receives grants/research support from National Institutes of Health (NIH). He serves as a consultant to Allergan, Inc.; Eli Lilly and Company; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Roche; Shire Pharmaceuticals Inc.; SK Pharma; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. He is a stockholder of AbbVie Inc.; Celgene Corporation; CeNeRx BioPharma; PharmaNeuroBoost,; Revaax Pharmaceuticals LLC; Seattle Genetics, Inc.; Xhale, Inc. He holds the patents to Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma (2012); National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost (2012); Xhale, Inc.; Skyland Trail. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; NovaDel Pharma, Inc. (2011); Skyland Trail. He receives income sources or equity of $10,000 or more from American Psychiatric Publishing; BioPharma; CeNeRx NovaDel Pharma, Inc.; PharmaNeuroBoost; Revaax Pharmaceuticals LLC; Xhale, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
CHV-010-050115-23
